Aclarion, Inc. (ACON) vs Biomerica, Inc. (BMRA)
A side-by-side comparison of Aclarion, Inc. and Biomerica, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ACON
Aclarion, Inc.
$2.36HealthcareDelayed quote: Oct 6, 2026, 9:30 AM EDT
BMRA
Biomerica, Inc.
$2.09HealthcareDelayed quote: Oct 6, 2026, 9:30 AM EDT
Total return — ACON vs BMRA
growth of $100 · dividends reinvested · last 4yACON -100.0% (-95.1%/yr)BMRA -94.3% (-51.1%/yr)BMRA compounded faster over this window
Log scale — wide-divergence pair
ACON BMRA
ACON vs BMRA: by the numbers
- •ACON is the larger company ($7M vs $6M market cap).
- •Both run net losses; BMRA's is the smaller (-84.79% vs -10978.48% net margin).
- •ACON grew revenue faster over the past five years (3.75% vs -9.17% CAGR).
Metrics side by side
Valuation
| Metric | ACON | BMRA |
|---|---|---|
| P/S ratio | 81.20 | 1.45 |
| P/B ratio | 0.40 | 2.46 |
Profitability
| Metric | ACON | BMRA |
|---|---|---|
| Gross margin | -291.27% | 8.09% |
| Operating margin | -9312.55% | -119.54% |
| Net margin | -10978.48% | -84.79% |
| ROE | -54.09% | -143.54% |
| ROIC | -57.11% | -117.93% |
Growth (annualized)
| Metric | ACON | BMRA |
|---|---|---|
| Revenue CAGR (5Y) | 3.75% | -9.17% |
| Total return CAGR (5Y) | N/A | -46.66% |
Frequently asked
- Which has grown faster, ACON or BMRA?
- Over the past five years, ACON grew revenue faster — ACON at a 3.75% CAGR versus BMRA at -9.17%.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.